A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RTA 1701 in Healthy Adults

Trial Profile

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RTA 1701 in Healthy Adults

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2018

At a glance

  • Drugs RTA 1701 (Primary)
  • Indications Autoimmune disorders; Inflammation
  • Focus Adverse reactions; First in man
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 20 Jun 2018 According to a Reata Pharmaceuticals media release, initial results are expected in the first half of 2019.
    • 20 Jun 2018 Status changed from planning to recruiting, according to a Reata Pharmaceuticals media release.
    • 09 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top